Revvity, Inc.
Revvity, Inc. Q2 FY26 Results — Earnings Call Analysis
Q2 FY26 earnings call: what management said on revenue, margins and capex.
What the Q2 FY26 call signalled
2 of 3 strong
The short version
- 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% to 4%. - 2026 Pro forma adjusted EPS guidance: $5.20 to $5.30, reflecting expected growth excluding China immunodiagnostics divestiture.
From Revvity, Inc.'s Q2 FY26 earnings-call transcript · updated 30 May 2026.
Revenue & Sales Performance
- 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% to 4%.
- First quarter 2026 pro forma organic growth was strong at 6%, exceeding expectations.
- Second quarter 2026 pro forma organic growth is guided at 2% to 3%, reflecting removal of the China immunodiagnostics business.
- Life Science Solutions expected to grow low single digits in Q2; Diagnostics expected mid-to-high single digits growth.
- Software business: mid-single digit organic growth expected for full year; Q2 software expected to decline around 20% due to tough comps but strong high teens growth anticipated in the second half of 2026.
- Signs of improvement in pharma/biotech spending with low single-digit growth in Q1 2026, signaling a slow but positive recovery.
- Reproductive health showing double-digit growth with strong instrument placements and reagent performance.
2 more points from Revvity, Inc.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Revvity, Inc. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company continues to be acquisitive to fill any portfolio gaps but currently does not see any large-scale M&A opportunities; tuck-in acquisitions are possible. (Page 13)
- The biggest capital deployment opportunity is share buybacks, and the company remains opportunistic and aggressive in this area. (Page 13)
- (Page 4, 12)
2 more points from Revvity, Inc.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Revvity, Inc. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Revvity, Inc. said on order book & pipeline — free account, 30 seconds.
Continue your research
Others in Life Sciences Tools and Services this season
- Medpace Holdings, Inc. (Q2 FY26)
Medpace Holdings, Inc. Q2 FY26 quarterly results analysis. Revenue is expected to remain within the current guidance range for 2026 despite higher cancellations
- Illumina, Inc. (Q2 FY26)
Illumina, Inc. Q2 FY26 quarterly results analysis. Illumina expects continued strong momentum in clinical sales, projecting mid-teens growth for the clinical ma
- Mettler-Toledo International Inc. (Q2 FY26)
Mettler-Toledo International Inc. Q2 FY26 quarterly results analysis. The company expects local currency sales growth of approximately 4% for full year 2026, in
- West Pharmaceutical Services, Inc. (Q2 FY26)
West Pharmaceutical Services, Inc. Q2 FY26 quarterly results analysis. Revenue growth guidance for 2026 increased to 7% to 9% organic growth, reflecting strong
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Revvity, Inc. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Revvity, Inc. Q2 FY26 results?
- 2026 revenue guidance updated to $2.81 billion - $2.84 billion, with pro forma organic growth expected at 3% to 4%. - 2026 Pro forma adjusted EPS guidance: $5.20 to $5.30, reflecting expected growth excluding China immunodiagnostics divestiture.
What is Revvity, Inc. share price analysis?
Revvity, Inc. currently shows a neutral. The stock trades at a P/E of 46.6 with a market cap of $11,292. Investors should review the full earnings analysis for detailed insights.
Is Revvity, Inc. planning capital expenditure?
- The company continues to be acquisitive to fill any portfolio gaps but currently does not see any large-scale M&A opportunities; tuck-in acquisitions are possible.
Keep Revvity, Inc. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.